COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year forecasts on Wednesday as sales growth of its ...

Third-quarter results will be the first for Mike Doustdar who was tasked in August with turning around the Danish company's ...

Pfizer and Novo Nordisk are in a heated battle to acquire obesity drug developer Metsera, driving legal and market tension.

The Trump administration is expected to announce deals with Eli Lilly and Novo Nordisk to cut prices of some weight loss ...

Eli Lilly led a Stocktwits poll, with 32% support, ahead of Novo Nordisk, Hims & Hers Health and Viking Therapeutics at 16%. ...

The dramatic bidding war kicked off last week with Novo's surprise play for Metsera, which had already agreed to be acquired ...

The boss of the Wegovy firm linked its reduced guidance to the market for weight-loss treatments being ‘more competitive than ...

Novo Nordisk has cut its outlook for 2025 as lower expectations for glucagon-like peptide-1 receptor agonists (GLP-1RA) continue to hit the drugmaker. Net profit for Q3 came in at Dkr20bn ($3.1bn), ...

Both companies have upped their offers for Metsera amid a bidding war, but Novo Nordisk comes armed with an extra $1.9bn.

The Trump administration is negotiating an agreement with pharmaceutical companies Novo Nordisk and Eli Lilly to offer some ...

Trump administration negotiating with Novo Nordisk and Eli Lilly to lower Wegovy, Zepbound prices to $149/month, with some ...

Ahead of a reported White House deal meant to lower the cost of obesity drugs like Wegovy, Novo said “intensifying ...